Filsuvez for Epidermolysis Bullosa Simplex
(FILS-EBS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new gel called Filsuvez to determine its effectiveness for individuals with epidermolysis bullosa simplex (EBS), a skin condition that causes painful blisters and wounds. The study aims to assess whether the gel can reduce blister count, accelerate wound healing, and improve daily comfort by alleviating pain and itching. Individuals with moderate to severe EBS who have active blisters on at least 3% of their skin may qualify for this trial. Participants will apply the gel for three months, followed by a follow-up visit two months later. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in EBS care.
Is there any evidence suggesting that Filsuvez is likely to be safe for humans?
Research has shown that Filsuvez, a gel derived from birch tree compounds, underwent safety testing in earlier studies. The most common side effects occur at the application site, including pain and itching. Some individuals have also experienced skin reactions or allergies, such as hives or rashes.
Despite these potential side effects, Filsuvez is generally considered safe and tolerable. Notably, trials have not identified any new safety issues so far. Prospective trial participants should discuss these potential side effects with the clinical team to determine if this treatment is suitable.12345Why do researchers think this study treatment might be promising?
Filsuvez is unique because it targets wound healing in Epidermolysis Bullosa Simplex (EBS) with a new approach. Unlike standard treatments that focus on symptom management, Filsuvez contains a plant-derived extract that promotes skin repair and reduces inflammation directly at the wound site. Researchers are excited about its potential to accelerate healing and improve skin integrity, offering a more proactive treatment option for EBS patients.
What evidence suggests that Filsuvez might be an effective treatment for epidermolysis bullosa simplex?
Research has shown that Filsuvez, a gel derived from birch tree compounds, may help treat epidermolysis bullosa simplex (EBS), a skin condition. In one study, over 40% of participants experienced complete wound healing in about 45 days. The gel reduces swelling, aids new skin growth, and strengthens the skin. Many patients have reported quicker healing and less bleeding. However, some studies found that Filsuvez did not significantly outperform a placebo (a treatment with no active ingredients) in closing wounds. Overall, early results suggest Filsuvez might aid in wound healing and improve comfort for people with EBS. Participants in this trial will apply Filsuvez to about 3% of their body surface area for 3 months, followed by a visit 2 months later.14678
Who Is on the Research Team?
Joyce Teng, MD, PhD, FAAD
Principal Investigator
Stanford University
Are You a Good Fit for This Trial?
This trial is for adults and children aged 6 months or older who have moderate to severe epidermolysis bullosa simplex (EBS), including Weber-Cockayne Syndrome. Participants should not have other major health issues that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants apply Filsuvez gel to about 3% BSA for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Filsuvez
Trial Overview
The study tests Filsuvez, a gel made from birch tree extracts, applied to the skin. Researchers want to see if it can safely reduce blisters, speed up wound healing, lessen pain and itching, and improve daily life for people with EBS.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All the participants will apply Filsuvez about 3% BSA for 3 months and a follow-up visit 2 months later.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Citations
Study Results | FILSUVEZ® (birch triterpenes) topical gel
more than 40% of participants who were treated with FILSUVEZ experienced complete wound closure in approximately one and a half months (45 days)
Efficacy data for FILSUVEZ® (birch triterpenes) topical gel
FILSUVEZ demonstrated efficacy and safety in the landmark EASE trial1,2* See the results after 3 months of treatment with FILSUVEZ3
Filsuvez® (Birch Triterpenes) Topical Gel
It promotes wound healing by modulating inflammation, encouraging new tissue formation, and maintaining the skin barrier. In a randomized, ...
4.
epidermolysisbullosanews.com
epidermolysisbullosanews.com/news/most-patients-report-beneficial-effect-filsuvez-eb-wounds/Most patients report beneficial effect from Filsuvez on EB ...
Overall, eight patients reported partial wound closure and faster healing, while three experienced less bleeding. Two had complete wound healing ...
5.
ema.europa.eu
ema.europa.eu/en/documents/assessment-report/filsuvez-epar-public-assessment-report_en.pdfFilsuvez, common name-birch bark extract - EMA
causes mild to moderate disease. Effects Table for Filsuvez in Epidermolysis Bullosa. Target wound closure in 45 days
Safety | FILSUVEZ® (birch triterpenes) topical gel
FILSUVEZ has established safety and tolerability · The most common side effect of FILSUVEZ is application site reactions, such as pain and itchy skin · No new ...
Safety | FILSUVEZ® (birch triterpenes) topical gel
Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of ...
About EB | FILSUVEZ® (birch triterpenes) topical gel
What is the most important safety information I should know? ... FILSUVEZ may cause a serious side effect of allergic reactions. Allergic reactions and skin ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.